全文获取类型
收费全文 | 465篇 |
免费 | 63篇 |
国内免费 | 13篇 |
专业分类
儿科学 | 14篇 |
妇产科学 | 1篇 |
基础医学 | 37篇 |
口腔科学 | 5篇 |
临床医学 | 55篇 |
内科学 | 221篇 |
皮肤病学 | 2篇 |
神经病学 | 12篇 |
特种医学 | 81篇 |
外科学 | 21篇 |
综合类 | 5篇 |
预防医学 | 29篇 |
眼科学 | 2篇 |
药学 | 26篇 |
中国医学 | 1篇 |
肿瘤学 | 29篇 |
出版年
2021年 | 3篇 |
2019年 | 3篇 |
2017年 | 7篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 3篇 |
2013年 | 7篇 |
2012年 | 3篇 |
2011年 | 4篇 |
2010年 | 8篇 |
2009年 | 5篇 |
2008年 | 8篇 |
2007年 | 13篇 |
2005年 | 13篇 |
2003年 | 6篇 |
2002年 | 6篇 |
2001年 | 6篇 |
2000年 | 3篇 |
1999年 | 7篇 |
1998年 | 23篇 |
1997年 | 19篇 |
1996年 | 18篇 |
1995年 | 17篇 |
1994年 | 12篇 |
1993年 | 11篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 11篇 |
1989年 | 21篇 |
1988年 | 38篇 |
1987年 | 25篇 |
1986年 | 28篇 |
1985年 | 24篇 |
1984年 | 24篇 |
1983年 | 21篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 7篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1975年 | 12篇 |
1974年 | 7篇 |
1973年 | 3篇 |
1972年 | 7篇 |
1970年 | 3篇 |
1969年 | 5篇 |
1968年 | 2篇 |
1967年 | 4篇 |
排序方式: 共有541条查询结果,搜索用时 15 毫秒
1.
目的快速鉴定血培养中的金黄色葡萄球菌和凝固酶阴性葡萄球菌(CoNS),结合临床快速判定是否为污染菌。方法采用荧光原位杂交法鉴定血培养中的金黄色葡萄球菌和CoNS,杂交结果若为CoNS,根据临床资料进行判断,并与文献推荐的污染判断法进行结果比较。结果探针的特异性经由标准菌株和临床分离菌株证实。金黄色葡萄球菌探针的特异性和敏感性均为100%,GoNS探针的特异性和敏感性分别为100%和95.5%。179株CoNS中117株判断为污染菌,污染率为68%,与文献推荐的污染判断方法一致。结论荧光原位杂交法适用于血培养中的金黄色葡萄球菌和CoNS的快速鉴定,以排除CoNS污染。 相似文献
2.
偏头痛大鼠脑内5-羟色胺1F和诱导型一氧化氮合酶基因的表达变化及针刺的干预效应 总被引:3,自引:0,他引:3
目的:前期实验已证实针刺治疗偏头痛疗效优越。观察针刺对偏头痛大鼠脑内5-羟色胺1F和诱导型一氧化氮合酶mRNA表达的调控作用。方法:实验于2005-11/2006-05在中南大学湘雅医院中西医结合研究所实验室完成。①选用SD大鼠40只,按随机数字表法分为4组(n=10),除正常对照组外,其余3组均复制大鼠偏头痛模型。模型对照组只造模,不作其他处理;针刺治疗组造模后进行针刺;针刺预防组针刺后造模电刺激20min。针刺方法:针刺大鼠双侧太冲、阳陵泉穴20min。采用疏密波,电流强度0.3~0.6mA,留针20min,1次/d,共5次。②实验完毕后取脑干及三叉神经节匀浆,采用反转录-聚合酶链反应法测定5-羟色胺1F和诱导型一氧化氮合酶mRNA表达。结果:进入结果分析正常对照组10只,模型对照组、针刺治疗组、针刺预防组各9只,共脱失3只。①与正常对照组比较,模型对照组大鼠诱导型一氧化氮合酶mRNA表达显著增强(P<0.01),5-羟色胺1FmRNA表达显著减弱(P<0.01)。②与模型对照组比较,针刺预防组和针刺治疗组诱导型一氧化氮合酶mRNA表达明显减弱(P<0.01),5-羟色胺1FmRNA表达显著增强(P<0.01)。结论:针刺调控5-羟色胺1F和诱导型一氧化氮合酶mRNA的表达可能是针刺防治偏头痛的分子机制。 相似文献
3.
Intrathecal baclofen for intractable spinal spasticity--a double-blind cross-over comparison with placebo in 6 patients. 总被引:1,自引:0,他引:1
H Hugenholtz R F Nelson E Dehoux R Bickerton 《The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques》1992,19(2):188-195
A group of six subjects with intractable spinal spasticity completed a double-blind cross-over paradigm in which they received two intrathecal bolus injections of baclofen solution five hours apart on two different days and two intrathecal bolus injections of placebo saline five hours apart on two other days. Each subject was repeatedly tested with a battery of clinical and physiological tests. In contrast to the placebo injections, the group responded to the baclofen injections with subjective and objective, clinically significant improvement in parameters of spasticity in their lower limbs, including muscle tone, frequency of spasms, hyperreflexia and passive range of joint motion. Furthermore, this improvement was maintained following thirty consecutive days of intrathecal bolus injections of baclofen at a fixed dose. 相似文献
4.
Retrorenal colon: implications for percutaneous diskectomy 总被引:1,自引:0,他引:1
It has been recommended that computed tomography (CT) with the patient prone be performed in every patient undergoing percutaneous diskectomy; this would enable detection of a retrorenal location of the colon, which could interfere with the percutaneous procedure. In this evaluation of 346 prone CT studies, only one patient (0.29%) was found to have retrorenal or retropsoas bowel that would have been perforated at diskectomy. Because of this extremely low prevalence, the performance of prone CT in every patient undergoing percutaneous lumbar diskectomy is not believed to be necessary. 相似文献
5.
6.
7.
8.
Values and limitations of transstenotic pressure gradients measured during percutaneous coronary angioplasty 总被引:2,自引:0,他引:2
P W Serruys W Wijns J H Reiber P de Feyter M van den Brand F Piscione P G Hugenholtz 《Herz》1985,10(6):337-342
The pressure gradient across coronary stenoses is measured routinely during angioplasty. Due to the finite size of the angioplasty catheter within the stenotic cross section, the remaining luminal area is further reduced and the transstenotic gradient may be overestimating the "true" pressure drop. This "true" pressure gradient can be approximated from the mean coronary blood flow and the stenosis geometry from theoretical models. Goal of this study was to assess the values and limitations of the in vivo measurements of the pressure gradient versus the calculated values. Therefore, flow in the great cardiac vein was measured in 13 patients before and/or after angioplasty of a proximal left anterior descending stenosis, not filled by collaterals. The Poiseuille and turbulent contributions to flow resistance were determined from stenosis geometry assessed by quantitative coronary angiography. A fourfold increase in the luminal area (from 0.7 mm2 pre- to 2.8 mm2 post angioplasty) was associated with a fourfold decrease in the in vivo measured transstenotic gradient (from 59 mm Hg pre- to 13 mm Hg post angioplasty). The occlusion area and the measured gradient were linearly correlated: gradient = 69-17 X occlusion area (r = 0.76). However, as expected, the transstenotic gradient systematically overestimated the theoretical gradient calculated from the laws of fluid dynamics. A nonlinear relation was found between the calculated gradient P and the occlusion area As: P = 15 X As-2 (r = 0.87). 相似文献
9.
David J. Stewart Brien Benoit Michael T. Richard Herman Hugenholtz Jean Dennery Neville Russell Eric Peterson Zvonimir Grahovac Garry Belanger Jean A. Maroun Vincent Young 《Journal of neuro-oncology》1984,2(1):53-58
Summary Twenty-six adult patients with astrocytomas were treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) 180–240 mg/m2 1.V. every 6–9 weeks, with metronidazole 1.5 g/m2 p. o. 12 h and 1 h before BCNU and again 6 h and 24 h after BCNU. Of twenty-two evaluable patients, 9 (41%) responded with evidence of reduced tumor size on CT scan, 3 (14%) stabilized and 10 (45%) failed. Patients with no prior chemotherapy or radiotherapy, good performance. status, low grade tumors, and age 50 years had the highest response rates, although differences were not statistically significant. Median survival and duration of response have not been reached with a median follow-up time of ten months. Hematological toxicity was dose-limiting and was probably not augmented by the metronidazole. There was one death from infection that was possibly drug-related. Gastrointestinal toxicity was substantial, and was probably increased by the metronidazole.While the combination of BCNU and metronidazole were tolerable, the response rate seen was no higher than that noted for BCNU alone, and further studies using this dose-schedule are not recommended in astrocytomas.Presented at the 13th International Congress of Chemotherapy, Vienna Austria, August 1983. 相似文献
10.
David J Stewart MD FRCP Michael T Richard Herman Hugenholtz Jean Dennery Dev Nundy Judith Prior Vital Montpetit Harry S Hopkins 《Journal of neuro-oncology》1984,2(4):315-324
Thirty-four consenting patients received VM-26 50–100 mg/m2 I.V. before surgical resection of intracerebral tumor, and drug was measured using a high pressure liquid chromatographic technique. Sufficient tumor for analysis was obtained from 29 patients. Brain metastases (13 patients) had higher concentrations of V M-26 than did gliomas (13 patients). Concentrations were comparable in brain metastases and meningiomas (3 patients). Prolonged (24 h) infusion of V M-26 did not appear to result in higher tumor drug concentrations in 5 patients than did rapid (1 h) infusion in 24 patients. Pretreatment with Amphotericin-B 10 mg/m2 12 h and 1 h before VM-26 did not appear to have any effect on VM-26 uptake into 4 intracerebral tumors, although data were limited, and VM-26 concentrations were very high in 1 metastasis. Pretreatment with oral glycerol 500 mg/kg 18 h, 12 h, 6 h, and immediately before I.V. VM-26 may have resulted in increased penetration of VM-26 into 9 tumors, although confirmation is required. Amphotericin-B, glycerol, and operative conditions did not appear to alter VM-26 plasma pharmacokinetics.VM-26
4-demethylepipodophyllotoxin 9-(4-6-O-thenylidene-B-D-glucopyranoside)
- VP-16
4-demethylepipodophyllotoxin 9-(4-6-O-ethylidene-B-D-glucopyranoside)
Presented in Part at the 74th Annual Meeting of the American Association for Cancer Research, San Diego, California, May 25–28, 183(1). 相似文献